+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nocturia Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309798
The global market for Nocturia Drugs was estimated at US$4.7 Billion in 2023 and is projected to reach US$7.2 Billion by 2030, growing at a CAGR of 6.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

What Are Nocturia Drugs and Why Are They Essential for Managing the Condition?

Nocturia is a medical condition characterized by excessive urination during the night, which can disrupt sleep and lead to daytime fatigue, reduced quality of life, and other health complications. Nocturia drugs are pharmaceutical treatments designed to manage the symptoms of this condition by reducing urine production, relaxing bladder muscles, or treating underlying causes such as overactive bladder, benign prostatic hyperplasia (BPH), or diabetes. These drugs include desmopressin, anticholinergics, alpha-blockers, and diuretics, which help patients manage frequent nighttime urination and improve their sleep patterns.

Nocturia drugs are important because they address a common yet often underdiagnosed condition that affects millions of people, particularly the elderly. Chronic nocturia can lead to sleep deprivation, which is associated with increased risks of cardiovascular disease, cognitive decline, and falls, especially in older adults. Effective treatment with nocturia drugs can significantly improve patients' sleep quality, overall health, and well-being, making them an essential component of healthcare for individuals dealing with this condition.

How Is the Nocturia Drugs Market Evolving?

The nocturia drugs market is evolving with the increasing awareness of nocturia as a medical condition and the growing demand for effective treatments. One of the key trends is the rising adoption of desmopressin-based drugs, which are highly effective in reducing nighttime urine production. These drugs mimic the natural hormone vasopressin, helping the kidneys absorb more water and reducing the frequency of urination during the night. As healthcare providers recognize the impact of nocturia on quality of life, desmopressin therapies are becoming more widely prescribed, particularly for elderly patients.

Another important trend is the development of combination therapies that target both bladder muscle relaxation and urine production. These therapies are designed to treat patients with complex conditions, such as those with overactive bladder or benign prostatic hyperplasia (BPH), who experience nocturia as a secondary symptom. Additionally, the market is seeing growth in patient-centered approaches, including personalized treatments based on individual symptoms, underlying conditions, and response to medication, which is enhancing the effectiveness of nocturia management.

Which Patient Groups Are Driving the Demand for Nocturia Drugs?

The demand for nocturia drugs is primarily driven by the aging population, as nocturia is more common among older adults. Elderly individuals often experience nocturia due to conditions such as overactive bladder, benign prostatic hyperplasia (BPH), or cardiovascular diseases that increase nighttime urine production. As life expectancy rises globally, the prevalence of nocturia is also increasing, driving demand for effective treatments to manage this condition.

Additionally, patients with underlying health conditions, such as diabetes or heart disease, are significant users of nocturia drugs. These conditions often lead to increased urine production, requiring targeted treatments to address nocturnal symptoms. Women experiencing postmenopausal changes and hormonal imbalances are another key demographic, as they are at higher risk of developing nocturia. Healthcare providers are increasingly recognizing nocturia as a condition that affects a wide range of patients, prompting a greater focus on comprehensive treatment strategies.

What Are the Key Growth Drivers in the Nocturia Drugs Market?

The growth in the nocturia drugs market is driven by several factors, starting with the increasing prevalence of nocturia among aging populations. As more elderly individuals experience this condition, the demand for medications that improve sleep and quality of life is rising. Healthcare providers are increasingly diagnosing and treating the condition, which is leading to a greater adoption of nocturia drugs, particularly desmopressin-based therapies.

Advances in drug development, including combination therapies and more targeted treatments, are also contributing to market growth. These innovations are improving the effectiveness of nocturia treatments, leading to better outcomes for patients with complex or severe symptoms. Additionally, the rising prevalence of chronic diseases, such as diabetes and cardiovascular conditions, is boosting demand for nocturia medications, as these conditions often contribute to nighttime urination. The growing focus on improving the quality of life for elderly patients is further driving the expansion of the nocturia drugs market.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Low Nocturnal Bladder Capacity Indication segment, which is expected to reach US$3.0 Billion by 2030 with a CAGR of a 6.3%. The Mixed Nocturia Indication segment is also set to grow at 6.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was valued at $1.3 Billion in 2023, and China, forecasted to grow at an impressive 5.6% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Nocturia Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Nocturia Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Nocturia Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AA Pharma Inc., Allergan PLC, Avadel Pharmaceuticals PLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 38 Featured):

  • AA Pharma Inc.
  • Allergan PLC
  • Avadel Pharmaceuticals PLC
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Urigen Pharmaceuticals, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Nocturia Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Nocturia Drives Demand for Effective Nocturia Drugs in Managing Urinary Disorders
  • Increasing Focus on Aging Populations Expands Market for Nocturia Drugs as a Key Treatment for Older Adults
  • Growing Adoption of Desmopressin-Based Drugs Strengthens Market for First-Line Treatment of Nocturia
  • Technological Advancements in Drug Delivery Systems Propel Growth in Fast-Acting and Long-Lasting Nocturia Medications
  • Rising Demand for Combination Therapies in Nocturia Management Expands Opportunities in Multimodal Treatment Approaches
  • Increasing Focus on Nocturia in Womens Health Fuels Growth in Gender-Specific Treatment Solutions
  • Growing Adoption of Nocturia Drugs in Treating Sleep Disorders Expands Market for Holistic Patient Care
  • Rising Awareness of Nocturia as a Comorbid Condition Strengthens Demand for Integrated Drug Therapies
  • Government Initiatives and Healthcare Reimbursement Policies Propel Market Growth for Nocturia Drugs in Public Health Systems
  • Technological Innovations in Nocturia Drug Formulations Drive Development of Patient-Friendly Treatment Options
  • Increasing Research on Nocturias Link to Cardiovascular Health Expands Opportunities for Targeted Drug Therapies
  • Rising Adoption of Nocturia Drugs in Overactive Bladder (OAB) Treatment Strengthens Market for Urology Therapies
  • Growing Use of Nocturia Drugs in Managing Prostate-Related Urinary Conditions Expands Market for Mens Health
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Nocturia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Nocturia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Nocturia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Nocturia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Low Nocturnal Bladder Capacity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Low Nocturnal Bladder Capacity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Low Nocturnal Bladder Capacity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Mixed Nocturia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Mixed Nocturia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Mixed Nocturia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Global Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Global Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Global Polyuria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Nocturnal Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Nocturnal Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Nocturnal Polyuria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Desmopressin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Desmopressin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Desmopressin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Anticholinergic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Anticholinergic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Anticholinergic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Antispasmodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Antispasmodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Antispasmodic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 35: USA Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: USA Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: USA 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Canada 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
JAPAN
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Japan 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
CHINA
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: China Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: China 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 53: China Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: China Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: China 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
EUROPE
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 56: Europe Recent Past, Current & Future Analysis for Nocturia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Nocturia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Nocturia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Europe 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 62: Europe Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Europe 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
FRANCE
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 65: France Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: France Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: France 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 68: France Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: France Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: France 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
GERMANY
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 71: Germany Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Germany 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 74: Germany Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Germany Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Germany 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
ITALY
  • Table 77: Italy Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: Italy 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 80: Italy Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Italy Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: Italy 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 83: UK Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: UK Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: UK 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 86: UK Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: UK Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: UK 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of Europe 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of Europe 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Nocturia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Asia-Pacific 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 101: Rest of World Recent Past, Current & Future Analysis for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 102: Rest of World Historic Review for Nocturia Drugs by Indication - Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 103: Rest of World 16-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Low Nocturnal Bladder Capacity, Mixed Nocturia, Global Polyuria and Nocturnal Polyuria for the Years 2014, 2024 & 2030
  • Table 104: Rest of World Recent Past, Current & Future Analysis for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 105: Rest of World Historic Review for Nocturia Drugs by Drug Type - Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 106: Rest of World 16-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Desmopressin, Anticholinergic Drugs, Antispasmodic, Antibiotics and Other Drug Types for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AA Pharma Inc.
  • Allergan PLC
  • Avadel Pharmaceuticals PLC
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Urigen Pharmaceuticals, Inc.

Table Information